A citation-based method for searching scientific literature

P Therasse, S G Arbuck, E A Eisenhauer, J Wanders, R S Kaplan, L Rubinstein, J Verweij, M Van Glabbeke, A T van Oosterom, M C Christian, S G Gwyther. J Natl Cancer Inst 2000
Times Cited: 13385







List of co-cited articles
139 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
29

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
9

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Riccardo Lencioni, Josep M Llovet. Semin Liver Dis 2010
8

Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner,[...]. N Engl J Med 2008
7

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
7

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
6

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem,[...]. Lancet 2018
4

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang,[...]. Lancet Oncol 2009
4


Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Haesun Choi, Chuslip Charnsangavej, Silvana C Faria, Homer A Macapinlac, Michael A Burgess, Shreyaskumar R Patel, Lei L Chen, Donald A Podoloff, Robert S Benjamin. J Clin Oncol 2007
4

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
Richard L Wahl, Heather Jacene, Yvette Kasamon, Martin A Lodge. J Nucl Med 2009
4


Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, Masafumi Ikeda, Peter R Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O Kaseb,[...]. N Engl J Med 2020
3


ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
E Van Cutsem, A Cervantes, R Adam, A Sobrero, J H Van Krieken, D Aderka, E Aranda Aguilar, A Bardelli, A Benson, G Bodoky,[...]. Ann Oncol 2016
3

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
3

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Robert J Motzer, Konstantin Penkov, John Haanen, Brian Rini, Laurence Albiges, Matthew T Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Negrier, Motohide Uemura,[...]. N Engl J Med 2019
3

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Robert Hawkins, Dmitry Nosov, Frédéric Pouliot, Boris Alekseev, Denis Soulières, Bohuslav Melichar,[...]. N Engl J Med 2019
3

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Marco Gerlinger, Andrew J Rowan, Stuart Horswell, M Math, James Larkin, David Endesfelder, Eva Gronroos, Pierre Martinez, Nicholas Matthews, Aengus Stewart,[...]. N Engl J Med 2012
3

Reporting results of cancer treatment.
A B Miller, B Hoogstraten, M Staquet, A Winkler. Cancer 1981
3



Preoperative chemoradiotherapy for esophageal or junctional cancer.
P van Hagen, M C C M Hulshof, J J B van Lanschot, E W Steyerberg, M I van Berge Henegouwen, B P L Wijnhoven, D J Richel, G A P Nieuwenhuijzen, G A P Hospers, J J Bonenkamp,[...]. N Engl J Med 2012
3


Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
David Cunningham, William H Allum, Sally P Stenning, Jeremy N Thompson, Cornelis J H Van de Velde, Marianne Nicolson, J Howard Scarffe, Fiona J Lofts, Stephen J Falk, Timothy J Iveson,[...]. N Engl J Med 2006
3

Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.
Karen Becker, James D Mueller, Christoph Schulmacher, Katja Ott, Ulrich Fink, Raymonde Busch, Knut Böttcher, J Rüdiger Siewert, Heinz Höfler. Cancer 2003
447
3

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder,[...]. Lancet 2017
2


Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.
Peter J Allen, Deborah Kuk, Carlos Fernandez-Del Castillo, Olca Basturk, Christopher L Wolfgang, John L Cameron, Keith D Lillemoe, Cristina R Ferrone, Vicente Morales-Oyarvide, Jin He,[...]. Ann Surg 2017
261
2

Global cancer statistics.
Ahmedin Jemal, Freddie Bray, Melissa M Center, Jacques Ferlay, Elizabeth Ward, David Forman. CA Cancer J Clin 2011
2

Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology.
E J Limkin, R Sun, L Dercle, E I Zacharaki, C Robert, S Reuzé, A Schernberg, N Paragios, E Deutsch, C Ferté. Ann Oncol 2017
285
2

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Yusuke Oji, Naoya Hashimoto, Akihiro Tsuboi, Yui Murakami, Miki Iwai, Naoki Kagawa, Yasuyoshi Chiba, Shuichi Izumoto, Olga Elisseeva, Ryo Ichinohasama,[...]. Int J Cancer 2016
30
6

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Shuichi Izumoto, Akihiro Tsuboi, Yoshihiro Oka, Tsuyoshi Suzuki, Tetsuo Hashiba, Naoki Kagawa, Naoya Hashimoto, Motohiko Maruno, Olga A Elisseeva, Toshiaki Shirakata,[...]. J Neurosurg 2008
147
2

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
2

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard S Finn, Peter R Galle, Josep M Llovet, Eric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim,[...]. Lancet Oncol 2019
666
2

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Arvind Dasari, Chan Shen, Daniel Halperin, Bo Zhao, Shouhao Zhou, Ying Xu, Tina Shih, James C Yao. JAMA Oncol 2017
2

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.
Bryan Oronsky, Patrick C Ma, Daniel Morgensztern, Corey A Carter. Neoplasia 2017
235
2

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker,[...]. J Clin Oncol 2009
2

Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Wui-Jin Koh, Nadeem R Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M Campos, Kathleen R Cho, Hye Sook Chon, Christina Chu, Rachel Clark, David Cohn,[...]. J Natl Compr Canc Netw 2019
391
2

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray. Int J Cancer 2015
2

Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.
Se Ik Kim, Jae Hyun Cho, Aeran Seol, Young Im Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song. Gynecol Oncol 2019
88
2

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall,[...]. N Engl J Med 2014
935
2

R1 Resection for Colorectal Liver Metastases: a Survey Questioning Surgeons about Its Incidence, Clinical Impact, and Management.
Luca Viganò, Guido Costa, Matteo Maria Cimino, Fabio Procopio, Matteo Donadon, Daniele Del Fabbro, Jacques Belghiti, Norihiro Kokudo, Masatoshi Makuuchi, Jean-Nicolas Vauthey,[...]. J Gastrointest Surg 2018
27
7

The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors.
Kazunari Sasaki, Daisuke Morioka, Simone Conci, Georgios A Margonis, Yu Sawada, Andrea Ruzzenente, Takafumi Kumamoto, Calogero Iacono, Nikolaos Andreatos, Alfredo Guglielmi,[...]. Ann Surg 2018
109
2

Is Tumor Detachment from Vascular Structures Equivalent to R0 Resection in Surgery for Colorectal Liver Metastases? An Observational Cohort.
Luca Viganò, Fabio Procopio, Matteo Maria Cimino, Matteo Donadon, Andrea Gatti, Guido Costa, Daniele Del Fabbro, Guido Torzilli. Ann Surg Oncol 2016
103
2

Hepatic vein management in a parenchyma-sparing policy for resecting colorectal liver metastases at the caval confluence.
Guido Torzilli, Fabio Procopio, Luca Viganò, Matteo Cimino, Guido Costa, Daniele Del Fabbro, Matteo Donadon. Surgery 2018
25
8

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.
Scott Kopetz, George J Chang, Michael J Overman, Cathy Eng, Daniel J Sargent, David W Larson, Axel Grothey, Jean-Nicolas Vauthey, David M Nagorney, Robert R McWilliams. J Clin Oncol 2009
845
2

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
2

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
172
2

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
2


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.